Daxiang Biotech

About Daxiang Biotech

Established in 2018, Daxiang Biotech is a high-tech company operating in the drug discovery tools sector. The founding team, which includes CEO Zhou Yu and comes from Peking University, aims to address the limitations of traditional animal models in drug development. The company is focused on developing and manufacturing human organoids-on-chips to enhance the efficiency, accuracy, and cost-effectiveness of pharmaceutical research and personalized medicine.

Daxiang Biotech develops bio-chip models that simulate the structural and functional units of human organs. Its core technology, IBAC®, combines organoids and organ-on-a-chip technologies to create a high-throughput, biomimetic platform for in-vitro model construction. This platform allows researchers to control the cellular micro-environment and replicate human organ activities to test drug responses. The product lineup includes various organoid-on-a-chip models for single-organ, multi-organ, and barrier functions like the blood-brain barrier, as well as equipment and kits for their use. The company provides services for pharmacology, toxicology, and basic scientific research based on these models.

The firm generates revenue by selling its organoid-on-a-chip products and providing related technical services. Its clientele consists of pharmaceutical companies and research institutions engaged in new drug research and development, disease modeling, and personalized precision medicine. A significant milestone was achieved in August 2020 with the launch of the first domestically produced commercial organ chips with independent intellectual property rights. The company has secured multiple rounds of venture capital funding, including a Series A round in May 2021 and a subsequent Pre-B round in November 2022, accumulating approximately $15.3 million in total. Strategic collaborations, such as the one with Nikon signed in April 2022, are in place to advance the development of organoid chip technology.